Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$11.55 USD
+1.06 (10.10%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $11.50 -0.05 (-0.43%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SMMT 11.55 +1.06(10.10%)
Will SMMT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SMMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SMMT
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
SMMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
Other News for SMMT
10 Health Care Stocks Whale Activity In Today's Session
Commit To Purchase Summit Therapeutics At $9, Earn 31.3% Annualized Using Options
Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
Ivonescimab’s Promising Trial Results and Potential Market Impact: A Strong Buy Recommendation